Article
Bioprinting of Human Primary and iPSC-derived Islets with Retained and Comparable Functionality
2024-10-16
Abstract excerpt
Currently, Type 1 diabetes (T1D) can be treated through implantation of allogenic islets, which replenish the beta cell population, however this method requires an extensive post-implantation immunosuppressant regimen. Personalized cellular therapy can address this through implantation of an autologous cell population, induced pluripotent stem cells (iPSCs). Cellular therapy, however, requires an encapsulation dev...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 13fc0b9e-fd78-5cbe-a2b7-e421220707aa
- DOI
- 10.1101/2024.10.14.617656
